Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R101933 (Laniquidar) with Taxanes in Refractory Metastatic Breast Cancer
NCT00028873Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2001
- Primary completion
- Jun 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of laniquidar in breast cancer, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Objective Response Rate and Clinical Benefit Rate. Started Sep 2001; status: completed.
02
Drugs
laniquidar
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00028873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028873.